Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
September 17, 2024 07:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal...
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
September 10, 2024 18:38 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON1 trial have been...
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
September 03, 2024 18:45 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s IPAX-1 Phase I study has been published in...
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
August 27, 2024 19:12 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United...
Telix Announces Reorganisation to Deliver on Strategic Priorities
August 26, 2024 19:17 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation...
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
August 22, 2024 04:27 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024. All...
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
July 29, 2024 07:30 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening of an expanded access program (EAP) in the United...
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
July 23, 2024 19:49 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, July 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA)...
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
July 17, 2024 19:14 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the...
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
July 10, 2024 21:40 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, July 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes proposed changes announced by the Centers for Medicare &...